Top

The power of
vascular innovation.

Imagine a readily available, “off the shelf ” bioengineered human acellular vessel (HAV)
that could replace a patients own blood vessel or create a new vascular access
for patients who require dialysis, without requiring cells or tissue from the patient.

Humacyte is making that happen.

What We Do

Groundbreaking
technology

Our unique process, paired with
innovation and continued improvement
and evolution, puts us at the forefront.

Who We Are

Making a
meaningful
impact on
patient care.

In the News

Humacyte Commences Phase II Vascular Trauma Trial

Humacyte Appoints Doug Blankenship as Chief Financial Officer

U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development

Bioengineered Blood Vessel Aims to Revolutionize Dialysis Access

What We Do

Why Human Accellular Vessels (HAV)?

From lower costs to fewer operations, HAVs may offer critical benefits.

Contact Us

We'd love to
hear from you.




Who We Are

Our path
to success.

With each year, we’ve moved
closer to lifesaving treatments.

Join Our Team

Join our team
and make
a difference.